Journal
CHEMMEDCHEM
Volume 7, Issue 1, Pages 159-170Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201100408
Keywords
GSK0660; inhibitors; NR1C2; nuclear receptors; PPAR ss; d; structure-activity relationships
Categories
Funding
- Deutsche Forschungsgemeinschaft [SFBTR17/A3]
- LOEWE-Schwerpunkt Tumor and Inflammation of the state of Hesse (Germany)
Ask authors/readers for more resources
GSK0660 (1) is the first peroxisome proliferator-activated receptor (PPAR) beta/delta-selective inhibitory ligand described in the literature. Based on its structure, we designed and synthesized a series of modified compounds to establish preliminary structureactivity relationships. Most beneficial for increased binding affinity towards the PPAR beta/delta ligand binding domain was the replacement of the 4'-aminophenyl substituent by medium-length n-alkyl chains, such as n-butyl or iso-pentyl. These compounds show activity down to the one-digit nanomolar range, thus possessing up to a tenfold higher binding affinity compared with GSK0660. Additionally, the subtype-specific inhibition of PPAR beta/delta was confirmed in a cell-based assay making these compounds invaluable tools for the further exploration of the functions of PPAR beta/delta.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available